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Abstract
Coenzyme Q (CoQ) is a key component of the mitochondrial respi-
ratory chain, but it also has several other functions in the cellular
metabolism. One of them is to function as an electron carrier in
the reaction catalyzed by sulfide:quinone oxidoreductase (SQR),
which catalyzes the first reaction in the hydrogen sulfide oxidation
pathway. Therefore, SQR may be affected by CoQ deficiency. Using
human skin fibroblasts and two mouse models with primary CoQ
deficiency, we demonstrate that severe CoQ deficiency causes a
reduction in SQR levels and activity, which leads to an alteration
of mitochondrial sulfide metabolism. In cerebrum of Coq9R239X
mice, the deficit in SQR induces an increase in thiosulfate sulfur-
transferase and sulfite oxidase, as well as modifications in the
levels of thiols. As a result, biosynthetic pathways of glutamate,
serotonin, and catecholamines were altered in the cerebrum, and
the blood pressure was reduced. Therefore, this study reveals the
reduction in SQR activity as one of the pathomechanisms associ-
ated with CoQ deficiency syndrome.
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Introduction
Primary and secondary coenzyme Q (CoQ) deficiencies are clinically
and genetically heterogeneous, with muscle, kidneys, and central
nervous system being the main affected organs and systems.
Because of the function of CoQ as antioxidant and as electron carrier
in the mitochondrial respiratory chain, increases in oxidative stress
and/or a decline in mitochondrial energy production and pyrimidine
biosynthesis have been identified as pathomechanisms of the
disease (Quinzii et al, 2008, 2010; Emmanuele et al, 2012).
Besides the antioxidant and bioenergetics functions, CoQ links
the mitochondrial electron transport chain to the TCA cycle by
succinate dehydrogenase (EC 1.3.5.1), to b-oxidation by electron-
transfer flavoprotein:ubiquinone oxidoreductase (EC 1.5.5.1), to the
shuttling of reduction equivalents from the cytoplasm by glycerol-3-
phosphate dehydrogenase (EC 1.1.99.5), to the synthesis of pyrim-
idines by dihydroorotate dehydrogenase (EC 1.3.3.1), to the metabo-
lism of glycine by choline dehydrogenase (EC 1.1.99.1), to arginine
and proline metabolism by proline dehydrogenase (EC 1.5.99.8),
and to sulfide metabolism by sulfide:quinone oxidoreductase (EC
1.8.99.1; SQR). However, the relative contributions of these path-
ways to the overall pathophysiology of CoQ deficiency have not
been evaluated so far, and only a defect in pyrimidine biosynthesis
in cell culture and a decline in the steady-state levels of SQR protein
in a proteomic analysis on heart and kidney of Coq9R239X mice have
been reported (Lopez-Martin et al, 2007; Lohman et al, 2014).
Sulfide:quinone oxidoreductase catalyzes the first step in the mito-
chondrial sulfide oxidation pathway. In this reaction, H2S is oxidized
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by SQR, forming a protein-bound persulfide. Two electrons from the
oxidation of H2S are transferred via flavin adenine dinucleotide to CoQ
and then to the electron transport chain. The SQR-bound persulfide is
transferred to an acceptor such as glutathione (GSH) or sulfite,
resulting in the generation of GSH persulfide (GSSH) or thiosulfate,
respectively (Fig 1). The persulfide group from GSSH is oxidized to
sulfite by a sulfur dioxygenase (EC 1.13.11.18; SDO) (also known as
ETHE1 or persulfide dioxygenase). Sulfite can then either be oxidized
to sulfate by sulfite oxidase (EC 1.8.3.1; SO) or converted to thiosulfate
via addition of a persulfide catalyzed by the thiosulfate sulfurtrans-
ferase or rhodanese (EC 2.8.1.1; TST). The sulfane sulfur from thiosul-
fate can be remobilized by another sulfurtransferase called thiosulfate
reductase (EC 2.8.1.3; TR) (Hildebrandt & Grieshaber, 2008; Kabil
et al, 2014; Libiad et al, 2014; Di Meo et al, 2015).
How low levels of CoQ affect SQR activity has been studied in
Schizosaccharomyces pombe mutant strains Ddps1 (homologue to
PDSS1) and Dppt1 (homologue to COQ2). In those mutant strains,
high accumulation of sulfide was reported (Uchida et al, 2000;
Zhang et al, 2008). In fission yeasts, sulfide is required for the
biosynthesis of both methionine and cysteine (Brzywczy et al,
2002). This latter aminoacid is required to synthesize glutathione,
an important antioxidant in mammalian cells. Curiously, CoQ-
deficient fission yeasts require cysteine and glutathione to grow on
minimal medium (Uchida et al, 2000).
In mammals, hydrogen sulfide is increasingly being recognized as
an important signaling molecule in both nervous and cardiovascular
systems. Increase in hydrogen sulfide levels induces an increase in
the concentration of serotonin and a decrease in norepinephrine,
aspartate, GABA, and glutamate (Skrajny et al, 1992; Roth et al,
1995). In the cardiovascular system, hydrogen sulfide induces
smooth muscle relaxation and enhances vasodilation (Kabil et al,
2014). Moreover, accumulation of hydrogen sulfide due to mutations
in ETHE1 has been associated with cytochrome oxidase (COX) defi-
ciency in ethylmalonic encephalopathy (Tiranti et al, 2009).
Based on those data, CoQ deficiency could induce a decrease in
SQR activity with a concomitant increase in hydrogen sulfide levels,
a fact that may contribute to the pathophysiology of CoQ deficiency.
Thus, in this study, we evaluate mitochondrial hydrogen sulfide
metabolism in cell and mouse models of CoQ deficiency due to
mutations in different CoQ biosynthetic genes (Appendix Fig S1),
with the aim of elucidating the pathophysiological consequences of
an alteration in this pathway.
Results
Primary CoQ deficiency causes a decline in SQR activity
As previously reported, the two mouse models of CoQ deficiency
used in this study, Coq9R239X and Coq9Q95X, have different residual
CoQ levels, resulting in different clinical phenotypes (Luna-Sanchez
et al, 2015). While Coq9R239X mice have 10–15% of residual CoQ
Figure 1. Hydrogen sulfide oxidation pathway in mammalian mitochondria.
SQR, sulfide:quinone oxidoreductase; TR, thiosulfate reductase; SDO, sulfur deoxygenase or ETHE1; SO, sulfite oxidase or SUOX; TST, thiosulfate sulfurtransferase or rhodanase.
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levels in cerebrum and kidney, Coq9Q95 mice have 40–50% of resid-
ual CoQ in the same tissues. In muscle, however, both mouse
models show similar CoQ levels, 10–20% as compared to wild-type
animals (Luna-Sanchez et al, 2015). As a result, Coq9R239X mice
develop a fatal mitochondrial encephalopathy, while Coq9Q95X mice
develop a late-onset mild mitochondrial myopathy (Garcia-Corzo
et al, 2013; Luna-Sanchez et al, 2015). Because CoQ acts as an elec-
tron acceptor in the reaction catalyzed by SQR in the mitochondrial
sulfide oxidation pathway, we first evaluated whether the deficit in
CoQ could affect mitochondrial H2S metabolism in these mouse
models. Thus, we first checked the consequences of low CoQ levels
on cerebral, renal, and muscular SQR of Coq9R239X and Coq9Q95X
mice at 3 months of age. The levels of Sqr mRNA were similar
between the three experimental groups (Fig 1A–C), and only a
reduction (by 25%) in kidneys of Coq9R239X mice was detected
(Fig 1B). At the protein level, the changes were more dramatic. The
levels of SQR protein were significantly reduced in cerebrum,
kidneys, and muscle of Coq9R239X mice, while Coq9Q95X mice only
showed reductions in the levels of SQR in muscle (Fig 1D and F). In
parallel to the reduction in SQR protein levels, the activity of SQR
was significantly reduced in kidneys and muscle of Coq9R239X and
Coq9Q95X mice (Fig 1G and H). While in kidneys, SQR activity in
Coq9R239X mice was lower than Coq9Q95X mice (Fig 1E), SQR activity
was similar in muscle of both mutant mouse strains (Fig 1F). In the
cerebrum, the SQR protein was only detected in isolated mitochon-
dria (Fig 1D) and no band was detected in tissue homogenate. This
reflects the low abundance of SQR in brain (Geiger et al, 2013)
(http://pax-db.org/protein/2093754/Sqrdl). Accordingly, we were
not able to measure SQR activity in cerebrum.
Based on the results obtained in Coq9 mutant mice, where SQR
levels and function were decreased in correlation with the residual
CoQ levels, we next evaluated if this alteration was also present in
primary CoQ-deficient skin fibroblasts due to mutations in different
CoQ biosynthetic genes. We used skin fibroblasts of patients with
severe CoQ deficiency due to mutation in PDSS2, COQ2, COQ4, and
COQ9 (Appendix Table S1 and Appendix Fig S2A). The four mutant
cells showed a reduction in the levels of SQR protein compared to
control cells (Fig 2B). While the treatment with 5 lM of CoQ10 for
1 day did not increase the SQR levels, after 7 days of treatment the
levels of SQR increased in the four mutant cells, confirming that the
low levels of CoQ10 were responsible for the SQR deficiency (Fig 2B).
These changes in SQR levels over the time after CoQ10 supplementa-
tion correlate with the increase in ATP levels previously reported
(Lopez et al, 2010). In vivo, supplementation with ubiquinol-10
(240 mg/kg bw/day) during 2 months in the Coq9R239X mouse
model increased the SQR levels in muscle (Fig 3F), while in
kidneys, a trend toward increase was observed (Fig 3E). These
changes correlate with the increase in CoQ levels on those tissues
after ubiquinol-10 supplementation (Fig 3C and D).
Low SQR activity induces changes in the proteins involved in the
mitochondrial hydrogen sulfide oxidation pathway
To know whether SQR deficiency has some impact on the mitochon-
drial hydrogen sulfide oxidation pathway, we first evaluated the
levels and activity of TST, which also takes part in this pathway, in
the tissues of mutant mice. An increase in TST levels was detected
in cerebrum of Coq9R239X mice (Fig 4A), while in kidneys and
muscle, the differences were not statistically significant (Fig 4B and
C). Nevertheless, TST activity was significantly increased in both
cerebrum and kidneys of Coq9R239X mice, while TST activity in the
same tissues of Coq9Q95X mice was similar to the activity in control
mice (Fig 4D and E). In muscle, where the activity of TST is lower
than in other two tissues, the TST activity was not altered in both
mutant mouse strains (Fig 4F). Coq9+/+, Coq9R239X, and Coq9Q95X
mice showed similarities in the levels of ETHE1 (SDO) in cerebrum,
kidneys, and muscle (Fig 4G–I). The levels of SUOX (SO) were
significantly higher in cerebrum of Coq9R239X mice compared to
those levels in Coq9+/+ and Coq9Q95X mice (Fig 4J). In kidneys and
muscle, however, the levels of SUOX were similar in the three
experimental groups (Fig 4K and L).
Disruption of the mitochondrial sulfide oxidation pathway
induces changes in thiols levels and metabolic disturbances in
the cerebrum of Coq9R239X mice
Because an alteration in the metabolization of hydrogen sulfide may
affect the levels of thiols, we then measured the levels of sulfides,
thiosulfate, sulfite, and glutathione in mouse tissues. The levels of
sulfides in the cerebrum of mutant mice were similar to those levels
in control mice (Fig 5A and B). In kidneys, however, the levels of
sulfides in Coq9R239X mice were higher than in Coq9+/+ and
Coq9Q95X mice (Fig 5A and B). The levels of thiosulfate and sulfite
were below the detection limit (5 lM) in all tested tissues.
The major non-protein thiol in cells is GSH, which is synthesized
in the cytosol and imported into mitochondria and into other orga-
nelles, where it plays an essential role in the antioxidant defense
against reactive oxygen species (ROS) (Ribas et al, 2014). The levels
of total GSH in the cytosol of cerebrum, muscle, and kidney were
significantly decreased in Coq9R239X mice (Fig 6A and Appendix Fig
S4A and B). However, the total GSH levels in mitochondria were
normal in the three tissues of Coq9R239X mice (Fig 6A and
Appendix Fig S2A and B). The activities of the GSH-utilizing
enzymes, GPx and GRd, were significantly decreased in the cytoso-
lic fraction of cerebrum of Coq9R239X mice compared to wild-type
animals (Fig 6B), while in muscle and kidney, the differences were
statistically significant for the renal GPx (Appendix Fig S2C and D).
The decrease in GPx and GRd activities in cerebrum of Coq9R239X
was due to a decline in the levels of GPx4 and GRd (Fig 6C and D).
These decreases in the glutathione enzymes did not modify the
GSSG/GSH ratios in cytosol and mitochondria (Appendix Fig S3).
Therefore, our results show a global depletion in the glutathione
system in cerebrum of Coq9R239X, a mouse model of mitochondrial
encephalopathy with severe histopathological signs of spongiform
degeneration and reactive astrogliosis in the cerebrum.
The GSH depletion in the cerebrum may be due to a decrease in the
levels of glutamate, one of the three amino acids components of GSH,
with the parallel increase in N-acetylglutamate (Fig 6E). In addition,
we found an increase in metabolites (L-tryptophan, 5-HIAA, and N-
acetyltryptophan) of serotonin biosynthesis (Fig 6E) and a decrease in
L-tyrosine (Fig 6E), which is essential in the biosynthesis of dopamine,
norepinephrine, and epinephrine, in the cerebrum of Coq9R239X mice.
To know whether the SQR deficiency is generally responsible for
the depletion in the glutathione system, we measured GSH after Sqr
silencing in Hepa1c1c7 cells. The silencing induced a significant
decrease in the levels of Sqr mRNA (Appendix Fig S4A) and SQR
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protein (Appendix Fig S4B). However, the total GSH did not change
in Hepa1c1c7 cells after Sqr silencing (Appendix Fig S4C). In the
mutant skin fibroblast with primary CoQ deficiency, where the SQR
deficiency is chronic but less severe than in mice tissues or after Sqr
silencing, the GSH levels were also similar to those levels in control
fibroblasts (Appendix Fig S4D).
A B C
D E F
G H
Figure 2. SQR levels and activity depend on CoQ levels in mice tissues.
A–H Sqr mRNA levels (A–C), SQR protein levels (D–F), and SQR activity (G, H) in cerebrum (A, D), kidneys (B, E, G), and muscle (C, F, H) of Coq9+/+, Coq9R239X, and Coq9Q95X
mice. Note that SQR Western blots were performed in isolated cerebral mitochondria due to the low levels of this protein in cerebrum. In kidneys and muscle, the
Western blots were performed in tissue homogenates. Data are expressed as mean  SD. *P < 0.05; **P < 0.01; ***P < 0.001; Coq9R239X and Coq9Q95X mice versus
Coq9+/+ mice. #P < 0.05; ##P < 0.01; ###P < 0.001; Coq9R239X versus Coq9Q95X mice (one-way ANOVA with a Tukey’s post hoc test; n = 5–9 for each group).
Source data are available online for this figure.
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H2S supplementation in wild-type animals induces changes in
neurotransmitters levels but does not alter mitochondrial sulfide
oxidation pathway
The changes observed in the levels of the proteins involved in mito-
chondrial sulfide oxidation pathway, as well as in the levels of
neurotransmitters in cerebrum of Coq9R239X mice may be attributed
to the increase in hydrogen sulfide. Thus, we treated control
fibroblast and wild-type mice with the H2S donor GYY4137. After the
treatment, the levels of SQR (Fig 7A) and TST (Fig 7B) did not
change in control fibroblasts. Also, TST levels were similar in kidneys
(Fig 7C) and cerebrum (Fig 7D) after the treatment compared with
the levels in untreated animals. Nevertheless, GYY4137 induced a
decrease in the levels of L-Glu and DA and an increase in the levels of
5-HIAA in cerebrum of Coq9+/+ mice (Fig 7E), a similar tendency
observed in the cerebrum of Coq9R239X mice (Fig 6E).
Pathophysiological consequences of reductions in CoQ levels and
SQR activity
It has been proposed that hydrogen sulfide metabolism influences
COX activity and regulates blood pressure (Kabil et al, 2014). COX
activity was, however, normal in cerebrum, kidneys, and muscle of
Coq9R239X and Coq9Q95X mice (Fig 8A). COX stain did not show any
signs of COX deficiency in the gastrocnemius muscle of Coq9R239X
and Coq9Q95X mice (Fig 8B).
The measurement of blood pressure in Coq9R239X mice
revealed a decrease in systolic and diastolic blood pressure
A C D
B
E F
Figure 3. Human skin fibroblasts and mouse tissues with primary CoQ10 deficiency exhibit increased SQR protein levels after exogenous CoQ10
supplementation.
A Levels of CoQ10 in fibroblasts of controls (C) and patients (P1-4) with primary CoQ10 deficiency.
B Levels of SQR protein in fibroblasts of controls (C) and patients (P1-4) with primary CoQ10 deficiency cultured without (vehicle) and with 5 lM of CoQ10 (+ CoQ10)
during 1 day or 7 days.
C, D Total CoQ levels (CoQ9 + CoQ10) in kidneys (C) and muscle (D) of Coq9
+/+, Coq9R239X, and Coq9R239X + ubiquinol-10 (Q10H2) mice.
E, F Levels of SQR protein in kidneys (E) and muscle (F) of Coq9+/+, Coq9R239X, and Coq9R239X + ubiquinol-10 (Q10H2) mice.
Data information: Data are expressed as mean  SD. **P < 0.01; ***P < 0.001; patients versus controls, as well as Coq9R239X versus Coq9+/+ mice. +P < 0.05; ++P < 0.01;
+++P < 0.001; + CoQ10 versus vehicle (one-way ANOVA with a Tukey’s post hoc test; n = 3–5 for each group).
Source data are available online for this figure.
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Figure 4. Changes in the proteins involved in the mitochondrial sulfide oxidation pathway in response to SQR deficiency in Coq9R239X mice.
A–C TST protein levels in cerebrum (A), kidneys (B), and muscle (C) of Coq9+/+, Coq9R239X, and Coq9Q95X mice.
D–F TST activity in cerebrum (D), kidneys (E), and muscle (F) of Coq9+/+, Coq9R239X, and Coq9Q95X mice.
G–I ETEH1 (SDO) protein levels in cerebrum (G), kidneys (H), and muscle (I) of Coq9+/+, Coq9R239X, and Coq9Q95X mice.
J–L SUOX protein levels in cerebrum (J), kidneys (K), and muscle (L) of Coq9+/+, Coq9R239X and Coq9Q95X mice.
Data information: Images in panels (C, F, and I) were obtained from the same membrane after stripping and re-blotting. Data are expressed as mean  SD. *P < 0.05;
**P < 0.01; ***P < 0.001; Coq9R239X and Coq9Q95X mice versus Coq9+/+ mice. #P < 0.05; ##P < 0.01; ###P < 0.001; Coq9R239X versus Coq9Q95X mice (one-way ANOVA with
a Tukey’s post hoc test; n = 5–9 for each group).
Source data are available online for this figure.
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as compared to age-matched wild-type animals (Fig 9A).
These changes were not related to the heart rate because the
beats per minute were similar in Coq9R239X and Coq9+/+ mice
(Fig 9B).
Discussion
Sulfide:quinone oxidoreductase is a mitochondrial enzyme that
requires CoQ as acceptor of electrons, thereby feeding electrons
A
B
Figure 5. Tissue levels of sulfides in CoQ-deficient mice.
A Quantification of sulfide levels in cerebrum and kidneys of Coq9+/+, Coq9R239X, and Coq9Q95X mice. Data are expressed as mean  SD. *P < 0.05; Coq9R239X and
Coq9Q95X mice versus Coq9+/+ mice. ##P < 0.01; Coq9R239X versus Coq9Q95X mice (one-way ANOVA with a Tukey’s post hoc test; n = 5–10 for each group).
B Qualitative measurement of hydrogen sulfide in cerebrum and kidneys of Coq9+/+ and Coq9R239X mice.
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A B
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Figure 6. Glutathione system and neurotransmitters biosynthesis are compromised in cerebrum of Coq9R239X mice.
A Total GSH in cytosol and mitochondria of cerebrum of Coq9+/+ and Coq9R239X mice.
B Cytosolic GPx and GRd activities in cerebrum of Coq9+/+ and Coq9R239X mice.
C, D Levels of GPx4 (C) and GRd (D) protein in cerebral homogenate of Coq9+/+ and Coq9R239X mice.
E Levels of L-glutamate (L-Glu), N-acetylglutamate (NacGlu), L-tryptophan (L-Trp), 5-HIAA, N-acetyltryptophan (NALT), L-tyrosine (L-Tyr) in cerebrum of Coq9+/+ and
Coq9R239X mice.
F Biosynthetic pathway of GSH, serotonin, and catecholamine.
Data information: Data are expressed as mean  SD. *P < 0.05; **P < 0.01; ***P < 0.001; Coq9R239X mice versus Coq9+/+ mice (t-test; n = 5 for each group).
Source data are available online for this figure.
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Figure 7. Supplementation with an H2S donor in wild-type animals induces changes in neurotransmitters levels.
A, B SQR (A) and TST (B) protein levels in human skin fibroblasts supplemented with the H2S donor GYY4137.
C, D TST protein level in kidneys (C) and cerebrum (D) of Coq9+/+ mice supplemented with the H2S donor GYY4137.
E Levels of neurotransmitters in cerebrum of Coq9+/+ mice supplemented with the H2S donor GYY4137.
Data information: Images in panels (A and B) were obtained from the same membrane after stripping and re-blotting. Data are expressed as mean  SD. **P < 0.01;
***P < 0.001; Coq9+/+ mice supplemented with GYY4137 versus Coq9+/+ mice (t-test; n = 4–6 for each group).
Source data are available online for this figure.
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into the mitochondrial electron transport chain (Hildebrandt &
Grieshaber, 2008; Modis et al, 2013). Low levels of CoQ may thus
affect the activity of SQR and its downstream reactions. Here, we
demonstrate that severe CoQ deficiency causes a dramatic reduction
in SQR levels and activity, which lead to an alteration of the mitochon-
drial sulfide metabolism. This pattern was observed in a mouse model
of primary CoQ deficiency as well as in skin fibroblasts of patients
with primary CoQ deficiency due to mutations in different CoQ
biosynthetic genes. The deficit in SQR induces changes in the mito-
chondrial sulfide oxidation pathway with modifications in the levels
of thiols. As a result, biosynthetic pathways of some neurotransmitters
were altered in the cerebrum and the blood pressure was reduced.
Therefore, this study reveals the reduction in SQR activity as one of
the pathomechanisms associated with the CoQ deficiency syndrome.
Low levels of CoQ induce a disruption in the mitochondrial
hydrogen sulfide oxidation pathway
In this work, we first investigated the tissue levels of Sqr mRNA and
SQR protein, as well as the SQR activity, in two mouse models of
A
B
Figure 8. COX activity in tissues from CoQ-deficient mice.
A COX activity in cerebrum, kidneys, and muscle of Coq9+/+, Coq9R239X, and Coq9Q95X mice. Data are expressed as mean  SD (one-way ANOVA with a Tukey’s post hoc
test; n = 3–6 for each group).
B Images COX histochemistry in gastrocnemius of Coq9+/+, Coq9R239X, and Coq9Q95X mice; scale bar: 100 lm.
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primary CoQ deficiency: the Coq9R239X mouse model with fatal
mitochondrial encephalopathy and the Coq9Q95X mouse model with
late-onset mild mitochondrial myopathy (Garcia-Corzo et al, 2013;
Luna-Sanchez et al, 2015). Our results confirm that the abundance
of the SQR protein is high in kidney, medium–low in muscle, and
very low in cerebrum (Geiger et al, 2013; http://pax-db.org/protein/
2093754/Sqrdl). However, the pattern of response to CoQ deficiency
is similar in the three tissues; that is, SQR protein levels and SQR
activity in cerebrum, kidneys, and muscle show a correlation
between the severity of CoQ deficiency and the decrease in SQR
protein levels and activity. Moreover, the deficit on SQR is not
limited to mutations in the Coq9 gene because similar results were
obtained in human skin fibroblasts with mutations in different CoQ
biosynthetic genes, that is, PDSS2, COQ2, COQ4, and COQ9. In the
mutant fibroblasts, CoQ10 depletion causes a significant impairment
of SQR-driven respiration, compared with control fibroblasts (Ziosi
et al, 2017). These results also point out that the deficit in SQR
occurs in human primary CoQ10 deficiency. Moreover, exogenous
supplementation with CoQ10 both in vitro and in vivo, in human and
mouse, increased the SQR levels in the mutant cells and mice. The
increase in SQR protein levels correlate with the increase in
SQR-driven respiration in presence of 5 lM of CoQ10 (Ziosi et al,
2017). This confirms that the levels of SQR depend on the levels of
CoQ and that exogenous CoQ10 supplementation may normalize SQR
levels and activity in patients with primary CoQ10 deficiency.
As a consequence of the reduced SQR levels, TST activity was
increased in cerebrum and kidneys. Interestingly, the cerebral TST
activity in Coq9R239X mice was increased at a higher magnitude (2.3-
fold increase) than the renal TST (1.3-fold increase), compared in
both cases with TST activity in control animals. This response is not
likely due to an increase in the hydrogen sulfide because the admin-
istration of the H2S donor GYY4137 did not increase TST levels in
control fibroblasts and wild-type mice. However, control cells have
normal SQR activity that can metabolize hydrogen sulfide. Therefore,
we cannot discard that such increases in TST enzyme in CoqR239X
mice may be a response to the high levels of hydrogen sulfide, which
probably lead to an increase in protein sulfhydration (Mustafa et al,
2009; Gao et al, 2015). As a consequence, the function of proteins
that can be regulated by this posttranslational modification would be
affected, and the expression of enzymes potentially involved in the
removal of persulfide groups, such as sulfurtransferases, might be
induced. Similarly, the levels of SO were only increased in cerebrum
of Coq9R239X compared to wild-type animals. Together, these data
point out that the disturbances in the mitochondrial hydrogen sulfide
oxidation pathway are more accentuated in the cerebrum of the
encephalopathic Coq9R239X mouse model.
A
B
Figure 9. Blood pressure and heart rate in Coq9R239X mice.
A Systolic, diastolic, and mean blood pressure in Coq9+/+ and Coq9R239X mice.
B Heart rate in Coq9+/+ and Coq9R239X mice.
Data information: Data are expressed as mean  SD. **P < 0.01; Coq9R239X mice versus Coq9+/+ mice (t-test; n = 5 for each group).
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Cerebrum of Coq9R239X mice shows depletion in the glutathione
system: a possible connection with the disruption in the
mitochondrial hydrogen sulfide oxidation pathway
Thiosulfate sulfurtransferase uses GSH and GSH metabolites in its
reaction. Therefore, changes in TST activity may induce alterations
in GSH metabolism. Moreover, GSH requires cysteine in its biosyn-
thesis, and this amino acid needs hydrogen sulfide for its biosynthe-
sis in fission yeasts (Brzywczy et al, 2002). In these organisms, the
addition of cysteine reduces the hydrogen sulfide production with
CoQ deficiency, suggesting that hydrogen sulfide and cysteine
biosynthetic pathways are coordinately regulated by feedback mech-
anisms (Zhang et al, 2008). While the sources of cysteine are appar-
ently different in mammals, the therapeutic effects of NAC, a
prodrug of L-cysteine utilized to increase GSH, in ETHE1 knockout
mice suggest that mitochondrial sulfide oxidation pathway may
exert some influence on GSH metabolism (Viscomi et al, 2010). In
fact, sulfur amino acid restriction increased expression of the
enzyme cystathionine c-lyase in mouse liver, resulting in increased
hydrogen sulfide production and decreased levels of GSH (Hine
et al, 2015). Our results showing depletion in the glutathione system
in cerebrum would validate this premise, confirming one of the
cytotoxic effects of hydrogen sulfide (Truong et al, 2006). However,
when we checked the direct relation between SQR and GSH systems
by transient silencing of SQR mRNA in Hepa cells, we did not obtain
a positive correlation. To test a long-term, but moderate, deficiency
in SQR, we measured GSH levels in human skin fibroblasts with
primary CoQ deficiency. However, also GSH levels were normal in
those cases. Thus, the GSH depletion in the cerebrum, kidney, and
muscle might be unrelated to the SQR deficiency or, if there is any
relation, this one should be linked with a long-term severe SQR defi-
ciency with increased TST activity because the latter enzyme might
play a key role in GSH metabolism (Remelli et al, 2012). Alterna-
tively, the depletion in the glutathione levels may be related to a
reduction in its precursors, for example, cerebral levels of L-gluta-
mate, an essential aminoacid for GSH biosynthesis, were decreased
in Coq9R239X mice. Moreover, it is important to note that the deple-
tion in GSH levels ran in parallel to a reduction in the levels and
activity of the GSH-utilizing enzymes GPx4 and GRd and these
changes may be critical for the increase in oxidative damage, neural
death, and astrogliosis observed in the cerebrum of Coq9R239X mice
(Seiler et al, 2008; Yoo et al, 2012; Garcia-Corzo et al, 2013).
Pathophysiological consequences of SQR deficiency
The changes in neurotransmitters biosynthesis in the cerebrum of
Coq9R239X mice are not limited to the reduction in L-glutamate but
also to the biosynthesis of serotonin and catecholamines. These
alterations might be a consequence of the disruption in hydrogen
sulfide metabolism because a dose-dependent and time-dependent
decrease in glutamate levels and increase in serotonin levels have
been described in the cerebrum and frontal cortex of rats chronically
exposed to 20 ppm and 75 ppm of hydrogen sulfide (Skrajny et al,
1992; Roth et al, 1995). The same authors reported a decrease in the
levels of norepinephrine with the exposure to 20 ppm of hydrogen
sulfide and an increase in those levels with the exposure to 75 ppm
of hydrogen sulfide (Skrajny et al, 1992). Norepinephrine and
epinephrine levels were, however, decreased in isolated porcine iris-
ciliary body exposed to increased concentrations of NaSH, which is
a commonly used hydrogen sulfide donor (Kulkarni et al, 2009).
The changes in the levels of L-glutamate, 5-HIAA, and dopamine
observed in wild-type animals after 2 weeks of supplementation
with the H2S donor GYY4173 confirm the influence of hydrogen sul-
fide in the levels of some neurotransmitters. Thus, the changes in
the biosynthesis of amino acid neurotransmitters may contribute to
the encephalopathy reported in patients and mice with fatal Coq9
mutations (Duncan et al, 2009; Garcia-Corzo et al, 2013; Luna-
Sanchez et al, 2015; Danhauser et al, 2016) and add new evidences
about the potential role of hydrogen sulfide as endogenous neuro-
modulator (Eto et al, 2002a,b). Curiously, multiple system atrophy,
a neurodegenerative disorder related to disruption in catecholami-
nes metabolism, neuronal death, and astrogliosis, and clinically
manifested with problems in movement and autonomic functions of
the body such as blood pressure regulation, has been recently asso-
ciated with mutations in COQ2 (Multiple-System Atrophy Research
Collaboration, 2013), a gene involved in CoQ biosynthesis (Ashby
et al, 1992; Uchida et al, 2000; Quinzii et al, 2006).
In the cardiovascular system, hydrogen sulfide regulates smooth
muscle contractility (Kabil et al, 2014). Generally, hydrogen sulfide
induces smooth muscle relaxation, but under particular conditions,
it may induces vasoconstriction (Hosoki et al, 1997; Kabil et al,
2014). Mice in which the Cse gene is disrupted exhibit hypertension
in comparison with wild-type animals (Yang et al, 2008), although
in a second and independent study, Cse KO mice were reported to
be normotensive (Ishii et al, 2010). Our results showing a decrease
in blood pressure in Coq9R239X mice would validate the role of
hydrogen sulfide in smooth muscle relaxation. However, we cannot
exclude that the decrease in blood pressure could also be the result
of the severe dysfunction in the brainstem (Garcia-Corzo et al,
2013), where the cardiac and vasomotor centers are localized to
regulate the autonomic functions of heart rate and blood pressure.
Nevertheless, in contrast to the Ndufs4 KO mice, another mouse
model of Leigh syndrome in which a low heart rate was associated
with the brainstem pathology (Quintana et al, 2012), the heart rate
was normal in Coq9R239X mice.
Finally, it has been also reported that hydrogen sulfide and/or its
metabolites can interfere with COX activity (Kabil et al, 2014; Szabo
et al, 2014). Our results did not show a decrease in COX activity in
the mutant mice, as it has been reported in ethylmalonic
encephalopathy due to mutations in ETHE1 (Tiranti et al, 2009).
However, the increase in hydrogen sulfide in ETHE1mice was higher
than in Coq9R239X mice, compared in both cases with hydrogen
sulfide levels in wild-type animals. Moreover, ETHE1 mice accumu-
late thiosulfate, while Coq9R239X mice do not (Tiranti et al, 2009; Di
Meo et al, 2011). Therefore, hydrogen sulfide and/or thiosulfate
must reach critical levels in order to produce toxic effects on COX
activity.
Conclusions
Our study demonstrates that primary CoQ deficiency is associated
with a disruption of the mitochondrial hydrogen sulfide oxidation
pathway, which may be a new pathomechanism associated with
this syndrome and may contribute to explain its clinical heterogene-
ity. According to that, primary CoQ deficiency may be considered
the first disease associated with a defect in SQR and, together with
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ETHE1 and SO deficiencies (Mudd et al, 1967; Garrett et al, 1998;
Mineri et al, 2008; Tiranti et al, 2009), the third disease occurring
with a defect in the mitochondrial hydrogen sulfide oxidation
pathway. Moreover, this new pathomechanism should be taken into
consideration for the treatment of primary CoQ deficiency and the
evaluation of new experimental therapies.
Materials and Methods
Mouse models and treatments
The Coq9R239X and Coq9Q95X mouse models were previously gener-
ated and characterized under mix of C57BL/6N and C57BL/6J
genetic backgrounds (Garcia-Corzo et al, 2013; Luna-Sanchez et al,
2015). Coq9R239X/+ mice were crossbreed in order to generate
Coq9+/+, Coq9R239X/+, and Coq9R239X/R239X (referred in the article
to as Coq9R239X). Coq9Q95X/+ mice were crossbreed in order to
generate Coq9+/+, Coq9Q95X/+, and Coq9Q95X/Q95X (referred in the
article to as Coq9Q95X). Only homozygous wild-type and mutant
mice between 3 and 5 months of age were used in the study.
Coq9R239X mice were treated with ubiquinol-10 (Q10H2) in the
drinking water in a dose of 240 mg/kg bw/day during 2 months,
as previously reported (Garcia-Corzo et al, 2014). Coq9+/+ mice
were treated with the H2S donor GYY4137 in the drinking water in
a dose of 50 mg/kg bw/day during 2 weeks (Hine et al, 2015).
Animals were genotyped and randomly assigned in experimental
groups. Equal number of males and females were assigned in
each experimental group, and no sex differences were observed
in the results. A total number of 152 mice were used in this
study, excluding breeders and heterozygous mice obtained in each
litter.
Mice were housed in the Animal Facility of the University of
Granada under an SPF zone with lights on at 7:00 AM and off at
7:00 PM. Mice had unlimited access to water and rodent chow. All
experiments were performed according to a protocol approved by
the Institutional Animal Care and Use Committee of the University
of Granada (procedures 92-CEEA-OH-2015) and were in accor-
dance with the European Convention for the Protection of
Vertebrate Animals used for Experimental and Other Scientific
Purposes (CETS # 123), the directive 2010/63/EU on the protection
of animals used for scientific purposes and the Spanish law
(R.D. 53/2013).
Cell culture and treatments
Primary mutant and control fibroblasts were grown in high glucose
DMEM-GlutaMAX medium supplemented with 10% FBS, 1% MEM
non-essential amino acids, and 1% antibiotics/antimycotic at 37°C
and 5% CO2. Control and mutant fibroblasts were treated with
5 lM CoQ10 during 1 or 7 days, as previously reported (Lopez et al,
2010). Control fibroblasts were treated with different concentrations
of the H2S donor GYY4137 for 5 days, as published elsewhere (Lee
et al, 2011).
The Hepa1c1c7 murine hepatoma cell line was obtained from cell
bank of the University of Granada and maintained in MEMa
GlutaMAX with 10% FBS and 1% antibiotics/antimycotics at 37°C
and 5% CO2.
Subcellular fractionation
Mitochondrial isolation was performed as previously described
(Fernandez-Vizarra et al, 2002). Tissues were homogenized in a
glass–Teflon homogenizer. Kidney was homogenized (1:4, w/v) in
the homogenization medium A (0.32 M sucrose, 1 mM EDTA,
10 mM Tris–HCl, ph 7.4); cerebrum was homogenized (1:5, w/v) in
the homogenization medium A plus 0.2% free fatty acids BSA, and
skeletal muscle was homogenized (1:20, w/v) with Ultraturex in
homogenization medium C (0.12 M KCl, 0.02 M HEPES, 2 mM
MgCl2, 1 mM EGTA, 5 mg/ml free fatty acids BSA). Kidney and cere-
brum homogenates were centrifuged at 1,000 × g for 5 min at 4°C to
remove nuclei and debris. Cytosol was collected from supernatants
after centrifuging at 14,400 × g for 2 min at 4°C and stored at 80°C
after the addition of Halt™ protease and phosphatase inhibitor cock-
tail (ThermoFisher). The mitochondrial pellet was washed and
suspended in homogenization medium and centrifuged again for
14,400 × g for 2 min at 4°C. The final crude mitochondrial pellet
was store at 80°C. Skeletal muscle homogenate was centrifuged at
600 × g for 10 min at 4°C. The supernatant (s1) was kept on ice, and
the pellet was re-suspended in 8 volumes of buffer A and centrifuged
at 600 × g for 10 min at 4°C. The subsequent supernatant (s2) was
combined with s1 and centrifuged at 17,000 × g for 10 min at 4°C. The
cytosolic supernatant obtained was stored at 80°C after the addition
of Halt™ protease and phosphatase inhibitor cocktail (ThermoFisher),
and the pellet obtained was re-suspended in 10 volumes of medium A
and centrifuged at 7,000 × g for 10 min at 4°C. The pellet was
re-suspended in 1 volume of medium B (0.3 M sucrose, 2 mM HEPES,
0.1 mM EGTA) and centrifuged at 3,000 × g for 10 min at 4°C.
Quantification of CoQ10 levels in human skin fibroblasts
After lipid extraction from homogenized cultured skin fibroblasts,
CoQ10 was determined via reversed-phase HPLC coupled to electro-
chemical (EC) detection (Lopez et al, 2010). The results were
expressed in ng CoQ10/mg protein.
Gene expression analyses
Total cellular RNA from frozen tissue was extracted and elec-
trophoresed in a 1.5% agarose gel to check the RNA integrity. RNA
from muscle and cerebrum samples was extracted with RNeasy
Fibrous Tissue Midi kit (for muscle) and RNeasy Lipid Tissue Mini
kit (for cerebrum) (Qiagen, Hilden, Germany) and treated with
RNase-Free DNase (Qiagen). RNA from kidney samples was
extracted with Real Total RNA Spin Plus Kit (Real). Total RNA was
quantified by optical density at 260/280 nm and was used to gener-
ate cDNA with High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Amplification was performed with quantita-
tive real-time PCR, by standard curve method, with specific Taqman
probes (from Applied Biosystems) for the targeted gene mouse Sqrdl
(Mm00502443_m1) and the mouse Hprt probe as a standard loading
control (Mm01545399_m1) (Luna-Sanchez et al, 2015).
Sample preparation and Western blot analysis in cells
For Western blot analyses in cerebrum, kidney, and muscle,
samples were homogenized in T-PER buffer (Thermo Scientific)
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with protease inhibitor cocktail (Pierce) at 1,100 rpm in a glass–
Teflon homogenizer. Homogenates were sonicated and centrifuged
at 1,000 × g for 5 min at 4°C, and the resultant supernatants were
used for Western blot analysis. For Western blot analyses in cere-
bral mitochondria, the pellets containing the mitochondrial fraction
were re-suspended in RIPA buffer with protease inhibitor cocktail.
For Western blot analyses in skin fibroblasts, cells were collected,
washed twice with 1× PBS, and homogenized in RIPA buffer with
protease inhibitor cocktail. Homogenates were centrifuged at
14,000 × g for 15 min at 4°C, and the resultant supernatants were
used for Western blot analysis. 60 lg of protein from the sample
extracts was electrophoresed in 12% Mini-PROTEAN TGX™ precast
gels (Bio-Rad) using the electrophoresis system mini-PROTEAN
Tetra Cell (Bio-Rad). Proteins were transferred onto PVDF 0.45-lm
membranes using a mini Trans-blot Cell (Bio-Rad) or Trans-blot Cell
(Bio-Rad) and probed with target antibodies. Protein–antibody
interactions were detected with peroxidase-conjugated horse anti-
mouse, anti-rabbit, or anti-goat IgG antibodies using Amersham
ECL™ Prime Western Blotting Detection Reagent (GE Healthcare,
Buckinghamshire, UK). Band quantification was carried out using
an Image Station 2000R (Kodak, Spain) and a Kodak 1D 3.6
software. Protein band intensity was normalized to VDAC1
(mitochondrial proteins) or GAPDH, and the data expressed in
terms of percent relative to wild-type mice or control cells
(Luna-Sanchez et al, 2015).
The following primary antibodies were used: anti-SQRDL
(Proteintech, 17256-1-AP), anti-TST (Proteintech, 16311-1-AP),
Anti-SUOX (Proteintech, 15075-1-AP), anti-ETHE1 (Sigma,
HPA029029), anti-GPx4 (Abcam, ab125066), anti-GRd (Santa Cruz
Biotechnology, sc-32886), anti-VDAC1 (Abcam, ab14734), and anti-
GAPDH (Santa Cruz Biotechnology, sc-166574).
Histochemical analysis of COX activity
Muscle samples (gastrocnemius) were freed from excess connective
tissue, embedded in OCT compound (Tissue-Tek), and oriented so
that fibers could be cut transversely. Samples then were snap-frozen
in precooled isopentane in liquid nitrogen. 8-lm-thick cryosections
were placed on Superfrost microscope slides at 20°C by using a
Leica CM1510S Cryostat and stained for detection of COX activity as
described previously (Tanji & Bonilla, 2008; Luna-Sanchez et al,
2015). The sections were examined, and digital images were
acquired using a Carl Zeiss Primo Star Optic microscope and a
Magnifier AxioCam ICc3 digital camera.
Enzymatic activities
Sulfide:quinone oxidoreductase activity was determined in isolated
mitochondria by following the enzymatic reduction rate of decylu-
biquinone at 275 nm upon sulfide addition (100 lM) (Hildebrandt
& Grieshaber, 2008; Theissen & Martin, 2008).
Thiosulfate sulfurtransferase activity was determined in isolated
mitochondria by measuring the formation of thiocyanate from
cyanide and thiosulfate (Sorbo, 1955; Hildebrandt & Grieshaber,
2008).
Cytochrome oxidase activity was measured in isolated mitochon-
dria following the reduction in cytochrome C (cyt C) at 550 nm
(DiMauro et al, 1987).
Glutathione peroxidase (GPx) and reductase (GRd) activities
were measured spectrophotometrically from cytosolic fractions
following the NADPH oxidation for 3 min at 340 nm on a Shimadzu
UV spectrophotometer (UV-1700; Duisburg, Germany) (Griffith,
1999; Lopez et al, 2006). The enzyme activities were expressed as
nmol/min/mg protein. In both cases, non-enzymatic NADPH oxida-
tion was subtracted from the overall rates.
Measurement of sulfides, thiosulfate, and sulfite
The concentrations of sulfite and thiosulfate were measured using
the monobromobimane HPLC method (Hildebrandt & Grieshaber,
2008). Additionally, hydrogen sulfide release was measured in
approximately 100 mg fresh tissue homogenate in passive lysis
buffer (Promega) supplemented with 10 mM Cys and 8 mM PLP. A
lead acetate hydrogen sulfide detection paper (Sigma) was placed
above the liquid phase in a closed Eppendorf tube and incubated for
5 h at 37°C until lead sulfide darkening of the paper occurred (Hine
et al, 2015).
GSH measurement
Glutathione measurements were performed in cytosol and mito-
chondrial fractions of mouse tissues, as well as in Hepa1c1c7 cells
and human skin fibroblasts, which were cultured in Opti-MEM
medium lacking FBS for 72 h in order to avoid influence of the GSH
contained in the FBS.
Glutathione was measured by an established fluorometric
method (Hissin & Hilf, 1976). Mitochondrial pellets were resus-
pended in sodium phosphate buffer (A) (100 mM sodium phos-
phate, 5 mM EDTA-Na2, pH 8.0). Mitochondrial and cytosolic
fractions were deproteinized with ice-cold TCA 40% and centrifuged
at 20,000 g for 15 min. For GSH measurement, the supernatant was
incubated with a solution of (A) and orthophthalaldehyde/ethanol
(B) (1 mg/ml) for 15 min at room temperature. The fluorescence of
the samples was then measured at 340 nm excitation and 420 nm
emission wavelengths in a spectrofluorometer plate reader (Bio-Tek
Instruments Inc., Winooski, VT, USA). For GSSG measurement, the
supernatant was preincubated with N-ethylmaleimide solution
(5 mg/ml) for 40 min and then alkalinized with 0.1 N NaOH (C).
Aliquots of these mixtures were then incubated with (B) and (C) for
15 min at room temperature. The fluorescence was then measured
as before. GSH and GSSG concentrations were calculated according
to standard curves prepared, and the levels of GSH and GSSG are
expressed in nmol/mg protein.
Metabolite quantification in the cerebrum
To quantify the metabolites in the cerebrum of Coq9+/+ and
Coq9R239X mice, frozen samples (80°C) were lyophilized (Virtis-
Benchtop K, Fisher Scientific, Spain) previous to sample homoge-
nization and metabolite extraction. The extraction/homogenization
method was adapted from Romisch-Margl et al (2012). Briefly,
metabolites were extracted from liver and brain samples by adding
300 ll of a mixture of precooled methanol/water (8:2, v/v) to
~50 mg of lyophilized sample and extracted/homogenized in 1.5-ml
microcentrifugation tubes with 1.4-mm stainless steel beads using a
bead-beating homogenizer (Bullet blender blue, Next Advance,
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USA) equipped with an integrated cooler unit. The tissues were
homogenized three times for 30 s at 6,000 rpm. Afterward, the
tubes were bath-sonicated for 1 min, incubated at 4 °C for 60 min,
and centrifuged at 5,000 × g for 15 min at 4°C. Supernatants were
analyzed by LC-(ESI)qTOF.
LC-HRMS analyses were performed according to Agilent
METLIN/PCDL method [2] using a 1290 infinity UHPLC coupled to
a 6550 ESI-QTOF (Agilent Technologies, USA) operated in positive
and negative electrospray ionization mode. Briefly, metabolites
were separated on Zorbax SB-Aq RR (50 × 2.1 mm., 1.8 lm)
column using a continuous gradient elution.
LC-HRMS data were deconvoluted using Find by Molecular
Feature algorithm from Mass Hunter Qualitative analysis software
(Agilent Technologies), and detected features were aligned across
samples using the Mass Profiler Professional (MPP) software (Agi-
lent Technologies). Relative quantification of metabolites was based
on peak area of each feature normalized by sample weight. Metabo-
lite identification was performed by using METLIN/PCDL database
with the ID browser extension from MPP software, which combines
retention time with accurate mass matching to provide greater confi-
dence in compound identification.
To figure out whether an increase in H2S was responsible for the
changes in neurotransmitters levels, L-glutamate, 5-HIAA, L-tyro-
sine, and dopamine were quantified in cerebrum of Coq9+/+ mice
and Coq9+/+ mice supplemented with GYY4137. The quantification
was performed by UHPL–CMS/MS following the method described
by Santos-Falinda and colleagues (Santos-Fandila et al, 2015).
Silencing SQR
SiRNA oligonucleotides, Silencer Select Pre-designed siRNAs (Life
Technologies, Carlsbad, CA, USA), were used for the transient
silencing of SQR. For SQR, the applied sequence contained the
50-30 sense, GCUCAGUAAACAUCCCGUUtt and antisense 30-50,
AACGGGAUGUUUACUGAGCca. This SQR-silencing siRNA
(Ambion s81773) was complementary with the mRNAs belonging
to RefSeq NM_001162503.1 and NM_021507.5 genes and also
targeted exon 3. For negative control, non-targeting siRNAs were
applied with the same chemical modifications for enhanced effi-
cacy as in other Silencer Select siRNAs (Ambion). Silencing was
conducted as described previously (Modis K, Faseb 2012). Cells
(80,000 cells/well) were seeded into 6-well tissue culture plates
and cultured in normal culture medium to reach 50% confluence.
At this point, the growth medium was replaced with Opti-MEM
medium lacking FBS and antibiotics/antimicotics, followed by
transfection with 25 pmol siRNA fragments per well at 30 nM
forming complexes with 7.5 ml of Lipofectamine RNAiMAX (Life
Technologies). Control cells were transfected in parallel with non-
targeting siRNA (Life Technologies).
Blood pressure and heart rate measurements in mice
Systolic blood pressure (SBP) and heart rate (HR) were measured in
conscious, prewarmed, and restrained mice by tail-cuff plethysmog-
raphy (Digital Pressure Meter LE 5001, Letica S.A., Barcelona,
Spain) as described previously (Gomez-Guzman et al, 2014).
Briefly, mice were held in a plastic tube, and their tail was put
through a rubber cuff, and the cuff was inflated with air. The
pressure level at which the first pulse appeared, after blood flow
had been interrupted with the inflated cuff, was designated SBP. At
least fifteen determinations were made in every session, and the
mean of the lowest ten values within 5 mmHg was taken as the SBP
level. HR values were obtained as average of several determinations
simultaneously to SBP level.
Statistical analysis
All statistical analyses were performed using the Prism 6 scientific
software. Data are expressed as the mean  SD of four–six experi-
ments per group. A one-way ANOVA with a Tukey’s post hoc test
was used to compare the differences between three experimental
groups. Studies with two experimental groups were evaluated using
unpaired Student’s t-test. A P-value of < 0.05 was considered to be
statistically significant.
Expanded View for this article is available online.
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The paper explained
Problem
Coenzyme Q (CoQ) has several functions in the cellular metabolism.
These functions may be differentially altered under CoQ deficiency,
resulting in different clinical presentations. So far, reductions in mito-
chondrial bioenergetics, pyrimidine biosynthesis, and b-oxidation, as
well as increases in oxidative damage and apoptosis, have been
described as pathomechanisms of CoQ deficiency syndrome.
Results
This study demonstrates that the severity of CoQ deficiency correlates
with the decrease in sulfide:quinone oxidoreductase (SQR) levels and
activity. The reduction in SQR activity leads to an alteration on mito-
chondrial hydrogen sulfide oxidation pathway, which results in a
modification in the levels of thiols and a decline in the glutathione
system. These changes may contribute to the bioenergetics impair-
ment, the increase in oxidative damage and the neuropathology.
Impact
Our study demonstrates that primary CoQ deficiency is associated with
a disruption of the mitochondrial hydrogen sulfide oxidation pathway, a
new pathomechanism associated with this syndrome. These findings
should be taken into consideration for the treatment of primary CoQ
deficiency and the evaluation of new experimental therapies. The
results shown in this article also consolidate the defects in sulfide
oxidation as a group of mitochondrial diseases. Furthermore, the data
shown here have important implications to elucidate the role of hydro-
gen sulfide in the regulation of COX activity, the modulation of blood
pressure, and its actions as neuromodulator.
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